Signals
7Dementia with Lewy bodies care formalises around alpha-synuclein-aware management
Cholinesterase inhibitor optimisation, antipsychotic-avoidance protocols, RBD recognition pathways, and emerging alpha-synuclein-targeted programs are reshaping DLB care.
Post-stroke spasticity therapy options widen past oral baclofen
Botulinum toxin maturity, intrathecal baclofen pump access, and emerging novel mechanism programs are reshaping post-stroke spasticity management.
Concussion and TBI biomarker tools mature
Plasma GFAP and UCH-L1 assays for concussion and traumatic brain injury are establishing routine emergency-department use.
ARIA monitoring infrastructure is the rate-limit on anti-amyloid uptake
Centres prescribing lecanemab and donanemab consistently report that MRI surveillance capacity, not patient demand or insurance approval, is the bottleneck on how many patients they can treat in 2026.
Plasma-biomarker rollout is concentrated at academic centers
Adoption of plasma p-tau217 testing remains concentrated at academic medical centers and large specialty practices, with community uptake meaningfully behind.
Lecanemab uptake constrained by infusion infrastructure, not demand
Real-world rollout of lecanemab is gated by infusion-chair capacity and MRI monitoring schedules - not by patient interest or prescriber willingness.
ARIA surveillance is becoming the rate-limiting step in anti-amyloid care
Amyloid-related imaging abnormalities require protocol-defined MRI at multiple intervals, and managing positive findings demands neurologist judgment that is in short supply.
Snapshots
2Spasticity therapy reference (2026)
Reference snapshot of spasticity therapy across post-stroke, multiple sclerosis, cerebral palsy, and spinal cord injury populations.
Acute ischemic stroke therapy reference (2026)
Reference snapshot of acute ischemic stroke therapy across thrombolysis and mechanical thrombectomy.